On August 4, TRANSTHERA-B rose 18% in regular trading, trading at HK$11.80 per share with turnover of HK$412 million, marking a significant volume-driven rebound from recent lows.

The rally was supported by broad strength across the Hong Kong-listed innovative drug sector, with peers including Yinuo Pharma up over 11%, BioAtla up over 5%, and Hutchmed and RemeGen up over 4%. Southbound capital has been actively adding positions in TRANSTHERA-B and other innovative drug names over the past month, while foreign institutional investors have also increased exposure.

Since July, the company has conducted consecutive share buybacks on the open market, repurchasing shares on at least seven trading days between July 17 and July 24, with cumulative spending exceeding HK$7 million. The buybacks were authorized under a plan approved at the June shareholder meeting allowing repurchases of up to HK$100 million. On July 24, the company also granted over 5.25 million H shares in equity incentives to 67 employees, further reinforcing alignment between management and shareholders.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)